Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in Globus Medical, Inc. $GMED

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Globus Medical, Inc. (NYSE:GMED) by 28.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,202 shares of the medical device company’s stock after selling 57,434 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.10% of Globus Medical worth $8,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. AQR Capital Management LLC increased its holdings in shares of Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after buying an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after acquiring an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock valued at $2,228,000 after acquiring an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp raised its position in Globus Medical by 237.3% during the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after purchasing an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after purchasing an additional 28,027 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $92.55 on Monday. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The stock has a market capitalization of $12.39 billion, a price-to-earnings ratio of 29.86, a P/E/G ratio of 1.37 and a beta of 1.06. The company’s 50 day moving average price is $89.30 and its 200-day moving average price is $70.45.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. The company had revenue of $769.05 million during the quarter, compared to analyst estimates of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, equities research analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMED has been the subject of a number of research reports. Royal Bank Of Canada upped their price objective on Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Canaccord Genuity Group upped their target price on Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Zacks Research downgraded shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Barclays boosted their price objective on shares of Globus Medical from $106.00 to $114.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Finally, Wells Fargo & Company increased their target price on shares of Globus Medical from $66.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.78.

Insider Buying and Selling

In other news, CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $363,353.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Leslie V. Norwalk sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $202,200.00. Following the transaction, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 91,636 shares of company stock valued at $7,984,583 over the last ninety days. Corporate insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.